Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Hold at StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Trading Up 2.1 %

Shares of Oramed Pharmaceuticals stock traded up $0.05 on Wednesday, hitting $2.40. The stock had a trading volume of 334,565 shares, compared to its average volume of 139,023. The stock has a market cap of $96.75 million, a price-to-earnings ratio of 21.82 and a beta of 1.70. Oramed Pharmaceuticals has a 52-week low of $2.00 and a 52-week high of $3.67. The company’s 50 day moving average price is $2.37 and its 200 day moving average price is $2.39.

Institutional Trading of Oramed Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its position in Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after buying an additional 10,774 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares in the last quarter. XTX Topco Ltd purchased a new position in Oramed Pharmaceuticals during the second quarter worth about $40,000. Murchinson Ltd. boosted its holdings in Oramed Pharmaceuticals by 23.2% in the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock valued at $4,369,000 after purchasing an additional 320,495 shares in the last quarter. Finally, BML Capital Management LLC increased its position in Oramed Pharmaceuticals by 62.1% during the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock worth $5,334,000 after purchasing an additional 837,153 shares during the period. 12.73% of the stock is owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.